Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005
2007

Trends in Antiretroviral Medication Use and Spending in U.S. Medicaid

publication Evidence: high

Author Information

Author(s): Jing Yonghua, Patricia Klein, Christina ML Kelton, Xing Li, Jeff J Guo

Primary Institution: University of Cincinnati

Hypothesis

The study aims to describe the trends in utilization of, spending on, and market shares of antiretroviral medications in the U.S. Medicaid Program.

Conclusion

The tremendous growth in antiretroviral spending is primarily due to rising utilization and the entry of newer, more expensive medications.

Supporting Evidence

  • The total number of prescriptions for antiretrovirals increased from 168,914 in 1991 to 3.0 million in 2005.
  • The total payment for antiretroviral drugs in the U.S. Medicaid Program increased from US$ 30.6 million in 1991 to US$ 1.6 billion in 2005.
  • NRTIs accounted for 50.8 percent of total spending on antiretrovirals in 2005.

Takeaway

This study shows that more people are using HIV medications, and the costs have gone up a lot over the years.

Methodology

Descriptive summary analyses of utilization and payment data from the Centers for Medicare & Medicaid Services from 1991 to 2005.

Limitations

The study could not analyze patient-specific clinical information or link utilization to patient demographics or disease prevalence.

Digital Object Identifier (DOI)

10.1186/1742-6405-4-22

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication